NCT06911931 · University of Rochester
Visual Perception in Schizophrenia
What this study is about
This study aims to identify novel markers of psychosis using electroencephalography (EEG).
View original scientific description
This study aims to identify novel markers of psychosis using electroencephalography (EEG).
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- All Subjects
- 20/32 visual acuity or better (using in-house optical correction, if necessary)
- An ability to speak English well enough to complete study assessments and to consent to the study
- Subjects with Schizophrenia-Spectrum Disorder
- Meets DSM-5 diagnostic criteria for schizophrenia, schizoaffective disorder, or schizophreniform disorder as confirmed by the Structured Interview for DSM-5 (SCID-5).
- Subjects with Bipolar Disorder
- Meets DSM-5 diagnostic criteria for bipolar disorder (type I, II, or unspecified) as confirmed by the Structured Interview for DSM-5 (SCID-5).
Exclusion criteria
- All subjects
- Presence of characteristics that could impair one's ability to comprehend the nature of the study, provide informed consent, or understand the assessment questions, including the following:
- Subject cannot read and understand the instructions well enough to complete the tasks or cannot provide informed consent.
- Intellectual impairment (WRAT-5 score \< 70) (at the discretion of experimenter);
- Actively intoxicated, as shown via patient self-report or staff report;
- Substance use disorder in the past 3 months;
- Subject considered high risk for suicidal acts (i.e., active suicidal ideation as determined by clinical interview OR any suicide attempt in 30 days prior to screening);
- Subject violence (involving severe/lethal means or violence occurring in prior 6 months) or extreme agitation.
- Being in a current manic state
- Head injury with loss of consciousness greater than 10 minutes (at the discretion of the experimenter).
- Subject has had electroconvulsive therapy (ECT) in the past 8 weeks;
- Diagnosed with a neurological condition (tumor, stroke, brain injury) or neurological disorder, including seizure disorders. Diagnosed with pervasive developmental disorder (phone screen or medical records)
- Lazy eye or squint or other known ocular pathology
- Healthy Control Subjects
- Any lifetime psychotic disorder or history of psychiatric hospitalization (self disclosure);
- Daily antidepressant, mood stabilizer or antipsychotic medication use in the last 6 months, or benzodiazepine use during the prior 2 days (self-disclosure); iii. First-degree relative(s) with a schizophrenia spectrum disorder (based on subject self-report) or bipolar disorder.
- Case-match Control Non-ill Subjects
- Any lifetime psychotic disorder (as assessed by SCID/or SSD);
- Recurrent depressive episodes or being in a current depressive episode (as assessed by SCID/or SSD)
- Persistent threshold psychotic symptoms
- History of psychiatric hospitalization;
- Daily antidepressant, mood stabilizer or antipsychotic medication use in the last 6 months, or benzodiazepine use during the prior 2 days
- First-degree relative(s) with a schizophrenia spectrum disorder (based on subject self-report) or bipolar disorder.
- Bipolar Subjects
- Persistent threshold psychotic symptoms
Where
- Rochester, New York
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Nov 12, 2025 · Source of record for eligibility and locations